SCHOLAR ROCK HOLDING CORPORATION (SRRK) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 72.24M USD | Liabilities, Current |
| Cash and equivalents | 437.09M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 55.00M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $72.24M | $437.09M | $55.00M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $59.64M | $430.54M | $49.40M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $55.42M | $323.53M | $44.04M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $61.97M | $286.77M | $82.86M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $50.44M | $152.93M | $142.09M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $37.57M | $137.93M | $226.45M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $46.94M | $177.88M | $259.40M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $39.37M | $76.39M | $62.67M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $32.99M | $93.37M | $97.12M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $37.51M | $91.98M | $146.45M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $32.74M | $101.86M | $178.08M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $26.73M | $67.60M | $151.04M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $24.27M | $108.06M | $140.67M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $26.21M | $151.28M | $124.00M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $36.39M | $103.28M | $212.09M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $33.74M | $133.07M | $210.58M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $40.16M | $305.73M | $64.96M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $33.37M | $100.17M | $110.04M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $64.30M | $212.84M | $40.16M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $64.60M | $176.13M | $70.30M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $67.02M | $206.92M | $75.30M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $69.95M | $159.11M | $155.58M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $42.56M | $160.36M | $180.67M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $32.87M | $56.23M | $60.04M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $32.57M | $115.13M | $26.05M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $27.10M | $95.43M | $65.21M | (m) | (m) | (m) |
| 2019-12-31 | $182.45M | $32.81M | $36.31M | $121.14M | $25.00M | (m) | 5.56× |
| 2019-09-30 | (m) | $32.52M | $32.64M | $143.44M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $32.05M | $113.80M | $71.33M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $34.08M | $67.00M | $92.66M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $31.12M | $115.07M | $60.58M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $5.76M | $103.99M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $6.68M | $115.06M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $5.02M | $56.46M | $1.50M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |